Glioblastoma (GBM) is an incurable brain cancer. Patients survive an average of 12-15 months post-diagnosis, despite receiving surgery and intensive chemoradiation because 100% of tumours grow back. Our inability to kill these tumours is likely because they consist of numerous distinct cancer cell populations defined by unique DNA and/or RNA profiles which confer some of them with the ability to resist treatment. It is these treatment-resistant cell subsets that we must specifically identify, characterise and learn how to kill. The aim of this project is to assess the transcriptional changes across GBM gene expression networks during therapy to highlight candidate molecules responsible for conferring (or facilitating transcriptional reprogramming to) a more treatment-resistant state.